13F reference period
Q2 2026
Security Snapshot
Nuvectis Pharma, Inc. - Common Stock, par value $0.00001 per share (NVCT) Institutional Ownership
CUSIP: 67080T108
13F Institutional Holders and Ownership History from Q1 2022 to Q3 2026
Institutions Reporting
81
Shares (Excl. Options)
10.24M
Full value: 10,235,371 · shares · 30 Jun 2026Price
$18.39
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.00001 per share
- Symbol
- NVCT on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 10,235,371
- Total 13F value
- $188,749,483
- Portfolio coverage rank
- 0%
- Share change
- +5,722,743
- Value change
- +$105,650,549
- Number of holders
- 81
- Shares outstanding
- 32,314,196
- SEC-reported price per share
- $20.13
- Insider filing price
- $20.13
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- NVCT - Nuvectis Pharma, Inc. - Common Stock, par value $0.00001 per share is tracked under CUSIP 67080T108.
- 81 institutions reported positions in Q2 2026.
- 1 significant owner is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 62 to 81 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$34.94M
Full value: $34,936,893 · USD · 31 Mar 2026.$188.75M
Full value: $188,749,483 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 81 institutions filings for Q2 2026.
Security key
67080T108
13F reference period
Q2 2026
13F holders
81
13D/G owners
1
CIK / CUSIP context first
Open Q2 2026 holders
NVCT full holder history
Nuvectis Pharma, Inc. SEC filings
Nuvectis Pharma, Inc. company facts
Nuvectis Pharma, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 67080T108:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
1
Security
NVCT
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Soleus Private Equity Fund III, L.P. | 5.1% | $30,389,563 | 1,648,024 | Soleus Capital Management, L.P. | 04 Aug 2026 |
As of 30 Jun 2026,
81
institutional investors reported holding
shares of
Nuvectis Pharma, Inc. - Common Stock, par value $0.00001 per share (NVCT).
This represents
32%
of the company’s total
outstanding shares.
10.24M
Full value: 10,235,371 · shares · 30 Jun 202632.31M
Full value: 32,314,196 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
30%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 4.8% | 1,550,000 | 1.3% | $28,504,500 | |
| BlackRock, Inc. | 3.1% | 1,001,285 | +31% | 0% | $18,413,632 |
| Soleus Capital Management, L.P. | 3.1% | 1,000,000 | 0.63% | $18,390,000 | |
| PERCEPTIVE ADVISORS LLC | 3.1% | 1,000,000 | 0.29% | $18,390,000 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.7% | 872,482 | +32% | 0% | $16,044,944 |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 2.4% | 777,078 | +19% | 4.9% | $14,290,464 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.3% | 432,273 | +13% | 0% | $7,951,022 |
| SPHERA FUNDS MANAGEMENT LTD. | 1.2% | 382,945 | 1% | $7,042,359 | |
| BALDWIN WEALTH PARTNERS LLC/MA | 1.2% | 382,015 | +0.9% | 0.46% | $7,025,256 |
| Occam Crest Management LP | 1.1% | 357,147 | -12% | 4.1% | $7,389,371 |
| Alyeska Investment Group, L.P. | 0.85% | 275,000 | 0.01% | $5,057,250 | |
| STATE STREET CORP | 0.77% | 248,198 | +49% | 0% | $4,564,361 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.67% | 217,286 | +106% | 0% | $3,995,890 |
| Avidity Partners Management LP | 0.62% | 200,000 | 0.59% | $3,678,000 | |
| NORTHERN TRUST CORP | 0.45% | 146,714 | +18% | 0% | $2,698,071 |
| VANGUARD FIDUCIARY TRUST CO | 0.39% | 127,554 | +11% | 0% | $2,345,718 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.37% | 118,297 | +28% | 0% | $2,175,482 |
| CITADEL ADVISORS LLC | 0.36% | 115,532 | +47% | 0% | $2,124,633 |
| Kalehua Capital Management LLC | 0.31% | 100,000 | 1.1% | $1,839,000 | |
| OPPENHEIMER & CO INC | 0.23% | 73,566 | 0% | 0.01% | $1,352,879 |
| UBS Group AG | 0.21% | 69,200 | +79% | 0% | $1,272,588 |
| CIBC Bancorp USA Inc. | 0.2% | 66,211 | +166% | 0% | $900,301 |
| FORBES J M & CO LLP | 0.18% | 59,000 | 0% | 0.09% | $1,085,010 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.18% | 57,133 | +15% | 0% | $1,050,676 |
| Informed Momentum Co LLC | 0.15% | 47,168 | 0.08% | $867,420 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
19
Headline period
Q2 2026
Rows shown
1-19 of 19
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 1,376,743 | $29,076,812 | +$844,038 | $21.12 | 17 |
| 2026 Q2 | 10,235,371 | $188,749,483 | +$105,650,549 | $18.39 | 81 |
| 2026 Q1 | 4,519,840 | $34,936,893 | +$2,076,848 | $7.73 | 62 |
| 2025 Q4 | 4,238,693 | $32,029,225 | +$4,308,822 | $7.55 | 47 |
| 2025 Q3 | 3,694,801 | $22,240,671 | +$875,366 | $6.02 | 52 |
| 2025 Q2 | 3,242,656 | $24,212,274 | +$8,414,990 | $7.47 | 46 |
| 2025 Q1 | 2,047,125 | $20,049,463 | +$7,527,323 | $9.77 | 33 |
| 2024 Q4 | 1,320,778 | $7,145,290 | +$1,393,786 | $5.41 | 31 |
| 2024 Q3 | 1,049,389 | $6,599,330 | -$771,215 | $6.29 | 31 |
| 2024 Q2 | 1,205,075 | $7,627,698 | -$2,433,916 | $6.33 | 40 |
| 2024 Q1 | 1,561,977 | $12,807,385 | +$393,490 | $8.20 | 40 |
| 2023 Q4 | 1,513,319 | $12,620,464 | +$1,886,095 | $8.34 | 36 |
| 2023 Q3 | 1,277,304 | $16,463,587 | +$85,915 | $12.89 | 33 |
| 2023 Q2 | 1,252,927 | $20,033,227 | +$12,444,259 | $15.97 | 37 |
| 2023 Q1 | 483,928 | $6,343,634 | -$3,188,708 | $13.11 | 13 |
| 2022 Q4 | 983,925 | $7,378,970 | +$968,656 | $7.50 | 11 |
| 2022 Q3 | 1,417,003 | $10,047,000 | +$5,345,357 | $7.09 | 9 |
| 2022 Q2 | 643,014 | $7,201,000 | +$370,284 | $11.20 | 10 |
| 2022 Q1 | 628,110 | $4,654,000 | +$4,654,000 | $7.40 | 7 |